Lionheart Health Files Patent for Bioelectric-Enhanced Klotho Nanoflowers Targeting Aging Reversal

Lionheart Health, Inc. announced the filing of a non-provisional U.S. patent covering its Bioelectric-Enhanced Klotho Nanoflowers platform for aging reversal and healthspan extension. The therapeutic system integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging.

The platform centers on engineered "nanoflowers"—flower-shaped hybrid nanoparticles capable of upregulating Klotho, a longevity-associated protein shown to improve brain, kidney, cardiovascular, and metabolic health. These nanoparticles restore mitochondrial function by enhancing ATP production and reducing oxidative stress while delivering targeted bioactive agents including peptides, plasmids, mRNA, and CRISPRa activators. The nanoflowers act as nanozyme catalysts that reduce reactive oxygen species and improve cellular resilience, with regenerative signaling enhanced when activated by precise bioelectric patterns.

Howard J. Leonhardt, Founder, Lead Inventor and Chief Executive Officer of Lionheart Health, stated that the invention represents the convergence of three powerful emerging technologies in biotechnology—bioelectric signaling, nanomedicine, and Klotho modulation. The company's goal is to create a system that reverses biological age at the cellular level and enhances healthspan safely, non-invasively, and affordably.

The nanoflowers are specifically engineered to respond to bioelectric fields, with signals increasing cellular uptake, intracellular transport, and activation of the nanoflower's catalytic and genetic payloads. Bioelectric stimulation is applied to open ion channels, improve endocytosis, direct nanoflowers toward mitochondria, and trigger therapeutic payload release. Klotho expression increases due to both nanoflower-delivered genetic or peptide payloads and bioelectric activation of promoter and epigenetic pathways, demonstrating a combined therapeutic benefit mechanism where neither component alone produces the full effect.

The platform is designed for system-wide healthspan improvement through mitochondrial biogenesis, reduction of cellular senescence, and stabilization of biological age. Klotho is recognized as one of the most promising longevity molecules, with decreased levels associated with accelerated aging, cognitive decline, inflammation, vascular calcification, kidney dysfunction, and frailty. Increasing Klotho expression has demonstrated benefits in preclinical models of brain aging, muscle repair, cardiac healing, kidney protection, and metabolic health.

Dr. Leslie Miller, Chief Medical Officer and former President of the International Society for Heart and Lung Transplantation, noted that bioelectric-enhanced Klotho nanoflowers provide a programmable, multi-modal tool to address root causes of aging—declining energy production, rising inflammation, and loss of regenerative capacity. The patent filing adds to Lionheart Health's intellectual property portfolio spanning bioelectric-controlled protein expression, stem-cell mobilization, tissue regeneration, mitochondrial restoration technologies, Klotho-based gene therapy, and regenerative aesthetic platforms.

Optional components include closed-loop adaptive control where sensors measure mitochondrial markers or electrophysiological signals to adapt stimulation patterns, and multi-modal integration combining nanoflowers with bioelectric stimulation, peptides, red light, PEMF, and regenerative support including cell and gene therapy. Therapy will be delivered in iterative sessions at baseline, 3-month, 6-month, and 12-month intervals in planned studies.

Lionheart Health is preparing for expanded clinical evaluation within its network of Lionheart Longevity & Wellness Licensed Clinics across the U.S. and internationally. The company plans to integrate bioelectric-enhanced Klotho nanoflowers into its XPRIZE Healthspan competition program. More information about the company's technologies is available at www.LionheartHealthStim.com, www.LionheartLongevity.com, and www.LeonhardtVentures.com.